Plasminogen Free Fibrin Sealant

机译：不含纤溶酶的纤维蛋白封闭剂

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

An affinity chromatographic resin using a tranexamic ligand for plasminogen removal effectively removed 96-99% of the plasminogen from the BAC component of Quixil/Crosseal. The resulting plasminogen free fibrin sealant was proven to be safe and effective in animal models of hemostasis. No neurotoxic effects were found in a rabbit craniotomy study. Clots formed from this fibrin sealant were more stable in vitro in the presence of urokinase than clots prepared from other fibrin sealants containing plasminogen plus a fibrinolytic inhibitor. The degradation kinetics of the fibrin sealant in vivo was not significantly different from three other marketed sealants (Quixil, Tisseel and Tissucol). In addition, the sealant reduced adhesion formation in a rabbit uterine horn model of adhesion prevention, where treated animals exhibited fewer adhesions than untreated controls.

机译：使用氨甲环磷酰胺配体去除纤溶酶原的亲和层析树脂可有效地从Quixil / Crosseal的BAC成分中去除96-99％的纤溶酶原。在止血动物模型中，所得的无纤溶酶原的纤维蛋白封闭剂被证明是安全有效的。在兔子开颅研究中未发现神经毒性作用。在存在尿激酶的情况下，由这种血纤蛋白封闭剂形成的凝块比由其他含有纤溶酶原加血纤蛋白溶解抑制剂的血纤蛋白封闭剂制备的血块在体外更稳定。纤维蛋白密封剂在体内的降解动力学与其他三种市售密封剂（Quixil，Tisseel和Tissucol）没有显着差异。此外，密封剂减少了兔子子宫角预防粘连模型中的粘连形成，在该模型中，经过处理的动物比未经处理的对照组表现出更少的粘连。

著录项

来源
《Society for Biomaterials Transaction Annual Meeting vol.29 pt.2》|2006年|429|共1页
会议地点 Pittsburgh,PA(US)
作者
Israel Nur; Lilliana Bar; Roberto Meidler; Anne J Gorman;
展开▼
作者单位

Omrix Biopharmaceuticals and Johnson & Johnson Wound Management;

展开▼
会议组织
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Enhancement of withstanding pressure of fibrin sealant by modified mixing ratio of fibrin sealant components for skull base reconstruction. [J] . Youichi Saitoh, Satoru Oshino Neurologia medico-chirurgica. . 2013,第1期

机译：通过修改血纤蛋白密封剂组分的混合比例来增强颅骨基重建所需的血纤蛋白密封剂耐压。
2. Enhancement of Withstanding Pressure of Fibrin Sealant by Modified Mixing Ratio of Fibrin Sealant Components for Skull Base Reconstruction —Technical Note— [J] . Youichi SAITOH, Satoru OSHINO Neurologia medico-chirurgica. . 2013,第1期

机译：通过修改纤维蛋白密封胶组分在颅底重建中的比例来提高纤维蛋白密封胶的耐压—技术说明—
3. Adverse effects of fibrin sealants in thoracic surgery: the safety of a new fibrin sealant: multicentre, randomized, controlled, clinical trial. [J] . Giuseppe Cardillo, Francesco Carleo, Luigi Carbone, European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery . 2012,第3期

机译：纤维蛋白密封剂在胸外科手术中的不良反应：新型纤维蛋白密封剂的安全性：多中心，随机，对照，临床试验。
4. Plasminogen Free Fibrin Sealant [C] . Israel Nur, Lilliana Bar, Roberto Meidler, Society for Biomaterials Transaction of the 31st Annual Meeting vol.XXIX pt.2 . 2006

机译：不含纤溶酶的纤维蛋白封闭剂
5. Autologous fibrinogen purification and concentration for use in fibrin sealant. [D] . Alston, Steven M., Jr. 2005

机译：自体纤维蛋白原的纯化和浓缩，用于纤维蛋白封闭剂。
6. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. [O] . O F Wagner, C de Vries, C Hohmann, 1989

机译：与纤维蛋白结合的1型纤溶酶原激活物抑制剂（PAI-1）与组织型纤溶酶原激活物（t-PA）或尿激酶型纤溶酶原激活物（u-PA）之间的相互作用。 t-PA / PAI-1复合物与t-PA的手指和kringle-2结构域介导的纤维蛋白结合。
7. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. [O] . Wagner, O F, de Vries, C, Hohmann, C, 1989

机译：与纤维蛋白结合的1型纤溶酶原激活物抑制剂（PAI-1）与组织型纤溶酶原激活物（t-PA）或尿激酶型纤溶酶原激活物（u-PA）之间的相互作用。 t-PA / PAI-1复合物与t-PA的手指和kringle-2结构域介导的纤维蛋白结合。

Plasminogen Free Fibrin Sealant

摘要

著录项

相似文献

相关主题

期刊订阅